How do insurance companies view cannabis treatments for AS? 

Despite growing interest in cannabis alternatives for ankylosing spondylitis, most insurance companies in the UK do not currently cover medical cannabis. Unlike traditional treatments such as NSAIDs or biologics, cannabis is still largely classified as a private therapy, leaving patients to cover costs out of pocket. 

This lack of insurance coverage presents a barrier for many, especially those already managing chronic illness expenses. Some patients still choose to pursue combined therapy, integrating cannabis with traditional medication to address specific symptoms like pain, sleep disturbance, or mood. While cannabis may offer faster relief timing, insurers are generally more likely to support treatments with long-standing regulatory approval. 

Key Considerations on Coverage 

Not routinely funded 

Even with a prescription, cannabis alternatives are rarely reimbursed under NHS or private insurance. 

Costs vs outcomes 

Patients often must weigh the financial burden against potential symptom improvements. 

Using both systems 

Those pursuing combined therapy typically rely on insurance for standard drugs and self-fund cannabis. 

Policy evolution 

As more data emerges, insurance coverage may eventually expand, but progress is slow. 

Visit providers like LeafEase to learn more about navigating access and funding for cannabis alternatives, including up-to-date guidance on what support might be available. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Ankylosing Spondylitis and medical cannabis.